阿卡波糖联合二甲双胍对2型糖尿病患者相关指标的影响
x
请在关注微信后,向客服人员索取文件
篇名: | 阿卡波糖联合二甲双胍对2型糖尿病患者相关指标的影响 |
TITLE: | |
摘要: | 目的:探讨阿卡波糖联合二甲双胍对2型糖尿病患者相关指标的影响。方法:100例2型糖尿病患者随机分为对照组(50例)和观察组(50例)。对照组患者给予阿卡波糖片50 mg,口服,每日3次;观察组患者在对照组治疗的基础上给予盐酸二甲双胍片0.5 g,口服,每日3次。两组疗程均为12周。观察两组患者治疗前后空腹血糖(FPG)、空腹血浆胰岛素(FINS)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)、餐后2 h胰岛素(2 hFINS)、胰岛素抵抗指数(HOMA-IR)、CD4+ T细胞中各Th细胞亚群比例、白细胞介素22(IL-22)、IL-17A、干扰素-γ(IFN-γ)水平及IL-22 mRNA、IL-17A mRNA、IFN-γ mRNA表达水平,并记录不良反应发生情况。结果:治疗后,两组患者FPG、FINS、HbA1c、2 hPG、2 hFINS、HOMA-IR、CD4+ T细胞中各Th细胞亚群比例、IL-22、IL-17A、IFN-γ水平及IL-22 mRNA、IL-17A mRNA、IFN-γ mRNA表达水平均显著低于同组治疗前,差异均有统计学意义(P<0.05);两组间除CD4+ T细胞中Th1细胞亚群比例比较差异无统计学意义(P>0.05) 外,其他指标均为观察组显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿卡波糖联合二甲双胍可有效控制2型糖尿病患者的血糖,改善胰岛抵抗状态,平衡Th细胞亚群,降低炎性细胞因子水平,且未增加不良反应的发生。 |
ABSTRACT: | OBJECTIVE: To investigate the effects of acarbose combined with metformin on related indexes of patients with type 2 diabetes mellitus. METHODS: A total of 100 patients with type 2 diabetes mellitus were randomly divided into control group (50 cases) and observation group (50 cases). Control group was given Acrbose tablet 50 mg orally, 3 times a day. Observation group was additionally given Metformin hydrochloride tablet 0.5 g orally, 3 times a day, on the basis of control group. Both groups were treated for 12 weeks. The levels of fasting plasma glucose (FPG), fasting plasma insulin (FINS), glycosylated hemoglobin (HbA1c), 2 h postprandial plasma glucose(2 hPG), postprandial 2 h insulin (2 hFINS), insulin resistance index (HOMA-IR), the proportion of Th cell subsets in CD4+ T cells,IL-22,IL-17A and IFN-γ, mRNA expression of IL-22,IL-17A and IFN-γ were observed in 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS: After treatment, FPG, FINS, HbA1c, 2 hPG, 2 hFINS, HOMA-IR, the proportion of Th cell subsets in CD4+ T cells, the concentrations of IL-22, IL-17A and IFN-γ, expression of IL-22 mRNA, IL-17A mRNA and IFN-γ mRNA in 2 groups were significantly lower than before treatment,with statistical significance (P<0.05); there was no significant difference in the proportion of Th1 in T cells between 2 groups(P>0.05). Other indexes of observation group were significantly lower than those of control group, with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS: For patients with type 2 diabetes mellitus, acarbose combined with metformin can effectively control the level of blood glucose, improve insulin resistance, balance Th cell subsets, reduce inflammatory factors levels but don’t increase the occurrence of ADR. |
期刊: | 2017年第28卷第27期 |
作者: | 庞宁,陈科,彭皓均,郑碧波 |
AUTHORS: | PANG Ning,CHEN Ke,PENG Haojun,ZHENG Bibo |
关键字: | 阿卡波糖;二甲双胍;2型糖尿病;CD4+ T细胞亚群;炎性细胞因子;胰岛素抵抗;血糖 |
KEYWORDS: | Acarbose; Metformin; Type 2 diabetes mellitus; CD4+ T cell subset; Inflammatory factors; Insulin resistance; Blood glucose |
阅读数: | 504 次 |
本月下载数: | 5 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!